Cibc World Markets Corp Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cibc World Markets Corp increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 19,153 shares of the biopharmaceutical company’s stock after buying an additional 2,201 shares during the period. Cibc World Markets Corp’s holdings in Regeneron Pharmaceuticals were worth $13,643,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the period. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC raised its position in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $678.42 on Tuesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The firm has a market cap of $74.17 billion, a price-to-earnings ratio of 17.72, a PEG ratio of 2.34 and a beta of 0.27. The business’s fifty day simple moving average is $694.15 and its two-hundred day simple moving average is $827.65. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $11.86 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Bank of America reissued an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.